International Lung Cancer Summit shared a post on X:
“SCLC is not a kinase driven disease.
At our 2025 Year in Review Charlie Rudin explained why we cannot simply copy the adenocarcinoma playbook. While we spent 20 years targeting driver oncogenes in NSCLC the future of small cell lies on the cell surface.
From tarlatamab to ADCs the new wave of efficacy comes from targeting unique surface antigens. Watch the full discussion with Solange Peters
and Martin Reck.”
Proceed to the video attached to the post.
More posts about International Lung Cancer Summit.